CAMBRIDGE, United Kingdom and NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- Artios Pharma Limited (œArtios), clinical-stage biotech company led by pioneers of DNA damage response (œDDR) drug...
ART0380 is a highly competitive, wholly owned ATR inhibitor with broad clinical application alone or in combination for DDR deficient and high replication stress tumors Phase 1 dose escalation data...
Artios Announces Initiation of Phase 2 Randomized Trial for ATR Inhibitor ART0380 plus Gemcitabine in Patients with Platinum Resistant Ovarian Cancer
Artios initiates Phase 2 study of Pol? Inhibitor ART4215
CAMBRIDGE, United Kingdom and NEW YORK, June 23, 2022 (GLOBE NEWSWIRE) -- Artios Pharma Limited (Artios), a clinical-stage biotech company pioneering the development of novel small molecule...
Phase 1a dose escalation of ART0380 defined initial regimen to be evaluated in Phase 1b setting.Phase 1a dose escalation demonstrated a predictable safety profile and no unexpected safety findings...
The round positions Artios, which is run by people behind pioneering DDR drug Lynparza, to test the effect of interfering with DNA repair processes.
The round positions Artios, which is run by people behind pioneering DDR drug Lynparza, to test the effect of interfering with DNA repair processes.
CAMBRIDGE, United Kingdom and NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company exploiting a broad DDR-based platform and small molecule drug design capabilities to develop a diverse pipeline of product candidates for the treatment of cancer, today announced the publication of a peer reviewed article titled, “Pol? inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance” in Nature Communications. Using novel small molecule tool compounds, the preclinical data generated in collaboration with researchers at the Institute for Cancer Research, London, and Cancer Research U.K., validates the Company’s approach to developing a potential first-in-class Pol? inhibitor, which demonstrated potent, selective Pol? inhibition, BRCA-gene synthetic lethality in a potentially PARP-resistant setting, and PARP inhibitor synergy.
Novartis has agreed to identify and validate next-generation DNA Damage Response (DDR) targets for precision cancer treatments using Artios Pharma’s discovery platform, through a collaboration that could generate more than $1.3 billion for Artios.